Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Cash, Cash Equivalents and Investments (Tables)

Note 5 - Cash, Cash Equivalents and Investments (Tables)

9 Months Ended

Sep. 30, 2024

Notes Tables

Cash, Cash Equivalents and Investments [Table Text Block]

		*Total*				*Quoted prices in active markets (Level 1)*				*Significant other observable inputs (Level 2)*				*Significant unobservable inputs (Level 3)*
September 30, 2024
Money market funds, included in cash equivalents		$	11,893			$	11,893			$	—			$	—
Total		$	11,893			$	11,893			$	—			$	—

		*Total*				*Quoted prices in active markets (Level 1)*				*Significant other observable inputs (Level 2)*				*Significant unobservable inputs (Level 3)*
December 31, 2023
Money market funds, included in cash equivalents		$	13,224			$	13,224			$	—			$	—
Investments - US treasuries			8,970				8,970				—				—
Total		$	22,194			$	22,194			$	—			$	—